AlzChem Group (ACT0) Aktievy
AlzChem Group AG, tillsammans med sina dotterbolag, utvecklar, producerar och marknadsför en rad kemiska specialiteter i Tyskland, Europeiska unionen, övriga Europa, Asien, NAFTA-regionen och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 4/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 1/6 |
ACT0 Community Fair Values
Create NarrativeSee what 56 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AlzChem Group AG Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €165.64 |
| 52 veckors högsta | €210.60 |
| 52 veckors lägsta | €123.20 |
| Beta | 0.39 |
| 1 månads förändring | 3.85% |
| 3 månaders förändring | -10.95% |
| 1 års förändring | 16.48% |
| 3 års förändring | 715.96% |
| 5 års förändring | 593.05% |
| Förändring sedan börsintroduktionen | 515.99% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 21
ACT: Integrated Calcium Chain And US Expansion Will Support Future Cash Flows
Analysts have raised their fair value estimate for AlzChem Group to about €254 from €200, citing recent research that highlights the company’s unique position in the calcium carbide and calcium cyanide value chain, along with updated assumptions for revenue growth, profit margins, and future P/E levels. Analyst Commentary Bullish analysts covering AlzChem Group highlight the company’s role in the calcium carbide and calcium cyanide value chain as a key support for current fair value assumptions and recent target price work.
Uppdatering av berättelse • Jul 07
ACT: Niche Calcium Chain Platform And Dividend Policy Will Shape 2026 Outlook
The analyst price target for AlzChem Group has increased from €192.07 to €204.49, with analysts citing the company's unique position in the calcium carbide and calcium cyanide value chain, along with recent supportive research, as key factors behind the revision. Analyst Commentary Recent research coverage on AlzChem Group highlights a mix of supportive and cautious views as analysts reassess where the stock should trade, with an emphasis on the company’s role in the calcium carbide and calcium cyanide value chain and how effectively it can convert that position into sustainable execution.
Uppdatering av berättelse • Jun 23
ACT: Specialty Platform And Value Chain Position Will Shape Cash Flow And Dividend
Analysts have lifted their price target on AlzChem Group by €4, from €173 to €177, citing recent research that highlights the company’s unique position in the calcium carbide and calcium cyanide value chain, as well as updated assumptions on discount rate, revenue growth, profit margin and forward P/E. Analyst Commentary Recent research on AlzChem Group highlights the company’s role in the calcium carbide and calcium cyanide value chain, but not all commentary is upbeat.Recent updates
Uppdatering av berättelse • Jul 21
ACT: Integrated Calcium Chain And US Expansion Will Support Future Cash Flows
Analysts have raised their fair value estimate for AlzChem Group to about €254 from €200, citing recent research that highlights the company’s unique position in the calcium carbide and calcium cyanide value chain, along with updated assumptions for revenue growth, profit margins, and future P/E levels. Analyst Commentary Bullish analysts covering AlzChem Group highlight the company’s role in the calcium carbide and calcium cyanide value chain as a key support for current fair value assumptions and recent target price work.Uppdatering av berättelse • Jul 07
ACT: Niche Calcium Chain Platform And Dividend Policy Will Shape 2026 Outlook
The analyst price target for AlzChem Group has increased from €192.07 to €204.49, with analysts citing the company's unique position in the calcium carbide and calcium cyanide value chain, along with recent supportive research, as key factors behind the revision. Analyst Commentary Recent research coverage on AlzChem Group highlights a mix of supportive and cautious views as analysts reassess where the stock should trade, with an emphasis on the company’s role in the calcium carbide and calcium cyanide value chain and how effectively it can convert that position into sustainable execution.Uppdatering av berättelse • Jun 23
ACT: Specialty Platform And Value Chain Position Will Shape Cash Flow And Dividend
Analysts have lifted their price target on AlzChem Group by €4, from €173 to €177, citing recent research that highlights the company’s unique position in the calcium carbide and calcium cyanide value chain, as well as updated assumptions on discount rate, revenue growth, profit margin and forward P/E. Analyst Commentary Recent research on AlzChem Group highlights the company’s role in the calcium carbide and calcium cyanide value chain, but not all commentary is upbeat.Uppdatering av berättelse • Jun 08
ACT: Specialty Chemicals Platform And Shareholder Moves Will Shape 2026 Outlook
Analysts have lifted their price targets on AlzChem Group by about €7 per share to roughly €192. This reflects updated views on fair value, discount rate assumptions and profitability that are broadly in line with recent research from Jefferies and Berenberg.Uppdatering av berättelse • May 24
ACT: Specialty Chemicals Moat And 2026 Expansions Will Support Future Cash Generation
Narrative Update on AlzChem Group The analyst price target for AlzChem Group has moved higher to €200, with analysts pointing to recent research that highlights confidence in the company’s specialty chemicals focus and its potential for high margin projects and cash generation in the coming years. Analyst Commentary Recent research shows a clear uptick in confidence from bullish analysts, with several price target revisions pointing to stronger conviction around AlzChem Group's specialty chemicals focus and project pipeline.Analysartikel • May 08
Investors Shouldn't Be Too Comfortable With AlzChem Group's (ETR:ACT) Earnings
Despite announcing strong earnings, AlzChem Group AG's ( ETR:ACT ) stock was sluggish. Our analysis uncovered some...Uppdatering av berättelse • May 01
ACT: Specialty Chemicals Moat And 2026 Expansions Will Drive Future Upside
Narrative update on AlzChem Group The analyst fair value estimate for AlzChem has been lifted by €5 to €200, with analysts citing recent price target increases from multiple firms and reinforcing views around the company's specialty chemicals focus, margin profile and potential long term value creation. Analyst Commentary Bullish analysts have been steadily lifting their price targets for AlzChem, pointing to the specialty chemicals focus and the margin profile as key supports for higher valuations.Uppdatering av berättelse • Apr 17
ACT: Specialty Platform And 2026 Expansions Will Underpin Cash Flow And Dividend Potential
Analysts have lifted their price targets on AlzChem to a range of about €195 to €197, reflecting updated models that incorporate a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally reduced future P/E. Analyst Commentary Recent research points to a broadly constructive stance on AlzChem Group, with several firms lifting price targets into a narrow band between about €195 and €197.Uppdatering av berättelse • Apr 03
ACT: Specialty Platform And 2026 Expansions Will Support Measured Long Term Upside Potential
The updated analyst price target for AlzChem Group has moved from €165 to €173, as analysts point to recent target increases on the Street and renewed confidence in the company's specialty chemicals focus and niche production platform. Analyst Commentary Recent Street research has centered on higher price targets for AlzChem Group, with several firms highlighting the specialty chemicals profile and niche positioning as key supports for their views.Uppdatering av berättelse • Mar 20
ACT: Specialty Chemicals Platform And 2026 Expansion Plans Will Support Upside
Analysts have lifted the implied fair value estimate for AlzChem Group to about €185 from roughly €177, supported by higher Street price targets in the €195 to €197 range and confidence in the company's specialty chemicals focus and production platform. Analyst Commentary Recent research updates point to a constructive tone from bullish analysts, who see the higher price targets as aligned with confidence in AlzChem Group's business model and execution around specialty chemicals.Uppdatering av berättelse • Mar 06
ACT: Specialty Chemicals Moat And 2026 Projects Will Drive Future Upside
Narrative Update on AlzChem Group The analyst price target for AlzChem Group has moved from €185 to €195, with analysts highlighting the company's specialty chemicals performance, unique production platform and high margin growth projects as key factors in their updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on AlzChem Group, pointing to recent research updates as support for higher valuation expectations and confidence in the company’s execution.Uppdatering av berättelse • Feb 19
ACT: New Creatine Capacity Plan Will Support Measured Long Term Upside Potential
Analysts are holding their price target for AlzChem Group steady at €165.00. They explain the unchanged view by pointing to updated assumptions that combine a slightly higher discount rate and P/E multiple with adjusted revenue growth and profit margin expectations.Uppdatering av berättelse • Feb 05
ACT: New Creatine Investment Program Will Support Long Term Upside Potential
Analysts have lifted their price target on AlzChem Group from €150.00 to €165.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple in their models. What's in the News AlzChem Group AG has approved an investment program of around €120 million aimed at supporting additional profitable growth and reinforcing its presence in specialty chemicals for sports, food, and health (company announcement).Analysartikel • Jan 23
Is AlzChem Group AG (ETR:ACT) Trading At A 33% Discount?
Key Insights AlzChem Group's estimated fair value is €231 based on 2 Stage Free Cash Flow to Equity Current share price...Uppdatering av berättelse • Jan 21
ACT: New Creatine Plant And 2025 Outlook Will Underpin Balanced Prospects
Analysts have modestly trimmed their price target for AlzChem Group to €176.94 from €179.93 as minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations feed into a slightly lower fair value estimate. What's in the News AlzChem Group AG approved an investment program of around €120 million to build a more automated production plant for creatine and its precursors, along with related infrastructure, targeting additional growth in sports, food and health (Key Developments).Uppdatering av berättelse • Jan 07
ACT: New Creatine Capacity Expansion And 2025 Record Outlook Will Support Upside
Analysts now set a higher fair value target for AlzChem Group at €179.93 compared with €167.10 previously. They point to updated assumptions for revenue growth, profit margins and a lower future P/E multiple.Uppdatering av berättelse • Dec 16
ACT: New Creatine Capacity And Partnerships Will Support Balanced Long Term Outlook
Analysts have raised their price target for AlzChem Group from €97.00 to €150.00, citing slightly stronger expectations for long term revenue growth and a higher justified future P E multiple, despite a modestly lower profit margin outlook. What's in the News AlzChem Group has approved an approximately EUR 120 million investment program to build a more automated creatine production plant and related infrastructure, targeting additional annual sales in the early triple-digit million euro range.Uppdatering av berättelse • Dec 02
ACT: Earnings Guidance And New Product Launch Will Drive Record Performance
Analysts have maintained their price target for AlzChem Group at €167.10. They cite steady outlooks for revenue growth and profit margins, with only minor adjustments to the discount rate and future earnings projections.Analysartikel • Nov 24
AlzChem Group AG's (ETR:ACT) Business Is Trailing The Market But Its Shares Aren't
With a price-to-earnings (or "P/E") ratio of 21.1x AlzChem Group AG ( ETR:ACT ) may be sending bearish signals at the...Uppdatering av berättelse • Nov 18
ACT: Strong Revenue Outlook And Product Launches Will Drive Upside Momentum
Analysts have raised their price target for AlzChem Group from €163.10 to €167.10, citing improved revenue growth forecasts. These improved forecasts have offset slight adjustments in the discount rate and profit margin expectations.Uppdatering av berättelse • Nov 02
ACT: Profitability Improvements And Product Launch Partnerships Will Support Fair Valuation
Analysts have raised their price target for AlzChem Group from €154.24 to €163.10. They cite improved profit margin projections and continued confidence in the company's financial outlook.Analysartikel • Oct 13
AlzChem Group AG (ETR:ACT) Shares Could Be 34% Below Their Intrinsic Value Estimate
Key Insights AlzChem Group's estimated fair value is €236 based on 2 Stage Free Cash Flow to Equity AlzChem Group's...Analysartikel • Sep 13
Is AlzChem Group (ETR:ACT) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Uppdatering av berättelse • Aug 20
Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
The increase in AlzChem Group’s consensus price target is primarily driven by a higher forward P/E multiple rather than changes in revenue growth forecasts, with fair value rising from €135.24 to €143.64. What's in the News AlzChem Group AG confirmed its full-year 2025 guidance, projecting organic sales growth of approximately 5% to around EUR 580 million.Analysartikel • Aug 20
Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?
While AlzChem Group AG ( ETR:ACT ) might not have the largest market cap around , it received a lot of attention from a...Uppdatering av berättelse • Aug 06
Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
AlzChem Group's higher consensus price target reflects improved profitability and a lower forward P/E, indicating stronger earnings expectations and valuation support, with fair value raised from €124.40 to €135.24. What's in the News AlzChem Group AG confirmed full year 2025 guidance, expecting approximately 5% organic sales growth to around EUR 580 million.Analysartikel • Aug 02
AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Investors in AlzChem Group AG ( ETR:ACT ) had a good week, as its shares rose 4.0% to close at €156 following the...Analysartikel • Jul 22
AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
AlzChem Group AG ( ETR:ACT ) shares have continued their recent momentum with a 25% gain in the last month alone. The...Analysartikel • Jun 02
Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysartikel • May 19
A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)
Key Insights AlzChem Group's estimated fair value is €119 based on 2 Stage Free Cash Flow to Equity AlzChem Group's...Analysartikel • May 05
What AlzChem Group AG's (ETR:ACT) 29% Share Price Gain Is Not Telling You
Despite an already strong run, AlzChem Group AG ( ETR:ACT ) shares have been powering on, with a gain of 29% in the...Analysartikel • May 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
AlzChem Group AG ( ETR:ACT ) will increase its dividend from last year's comparable payment on the 13th of May to...Analysartikel • May 01
Is It Too Late To Consider Buying AlzChem Group AG (ETR:ACT)?
AlzChem Group AG ( ETR:ACT ), might not be a large cap stock, but it received a lot of attention from a substantial...Analysartikel • Mar 28
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
The board of AlzChem Group AG ( ETR:ACT ) has announced that it will be paying its dividend of €1.80 on the 13th of...Analysartikel • Mar 18
With EPS Growth And More, AlzChem Group (ETR:ACT) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysartikel • Mar 05
AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets
Investors in AlzChem Group AG ( ETR:ACT ) had a good week, as its shares rose 6.3% to close at €77.80 following the...Analysartikel • Mar 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
AlzChem Group AG's ( ETR:ACT ) periodic dividend will be increasing on the 13th of May to €1.80, with investors...Analysartikel • Feb 19
Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)
With a price-to-earnings (or "P/E") ratio of 14.1x AlzChem Group AG ( ETR:ACT ) may be sending bullish signals at the...
Ny berättelse • Feb 17
Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
Strategic expansion in production capacities and collaboration with the U.S. Department of Defense could bolster long-term revenue and market diversification.Analysartikel • Nov 14
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
AlzChem Group AG ( ETR:ACT ) just reported healthy earnings but the stock price didn't move much. Investors are...Analysartikel • Oct 27
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
AlzChem Group AG ( ETR:ACT ) shareholders would be excited to see that the share price has had a great month, posting a...Analysartikel • Oct 18
When Should You Buy AlzChem Group AG (ETR:ACT)?
AlzChem Group AG ( ETR:ACT ), might not be a large cap stock, but it saw a significant share price rise of 46% in the...Analysartikel • Sep 07
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Jun 04
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, AlzChem Group fair value estimate is €43.94 AlzChem Group's...Analysartikel • May 08
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
AlzChem Group AG's ( ETR:ACT ) recent earnings report didn't offer any surprises, with the shares unchanged over the...Aktieägarnas avkastning
| ACT0 | DE Chemicals | DE Marknad | |
|---|---|---|---|
| 7D | 3.3% | -1.4% | 1.0% |
| 1Y | 16.5% | 16.3% | 4.7% |
Avkastning vs industri: ACT0 matchade German Chemicals branschen som gav 16.3 % under det senaste året.
Avkastning vs Marknaden: ACT0 översteg German marknaden som gav 4.7 % under det senaste året.
Prisvolatilitet
| ACT0 volatility | |
|---|---|
| ACT0 Average Weekly Movement | 4.8% |
| Chemicals Industry Average Movement | 3.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stabil aktiekurs: ACT0 har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för German.
Volatilitet över tid: ACT0 s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1908 | 1,680 | Andreas Niedermaier | www.alzchem.com |
AlzChem Group AG, tillsammans med sina dotterbolag, utvecklar, producerar och marknadsför en rad kemiska specialprodukter i Tyskland, EU, övriga Europa, Asien, NAFTA-regionen och internationellt. Verksamheten bedrivs genom tre segment: Specialty Chemicals, Basics & Intermediates samt Other & Holding. Segmentet Specialty Chemicals säljer kemiska specialprodukter som används inom kemi-, livsmedels-, djurfoder-, försvarsteknik- och förnyelsebar energiindustrierna.
AlzChem Group AG Sammanfattning av grunderna
| ACT0 grundläggande statistik | |
|---|---|
| Börsvärde | €1.63b |
| Vinst(TTM) | €67.77m |
| Intäkter(TTM) | €593.80m |
24.7x
P/E-förhållande2.8x
P/S-förhållandeÄr ACT0 övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ACT0 resultaträkning (TTM) | |
|---|---|
| Intäkter | €593.80m |
| Kostnad för intäkter | €204.09m |
| Bruttovinst | €389.71m |
| Övriga kostnader | €321.94m |
| Intäkter | €67.77m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
Oct 29, 2026
| Vinst per aktie (EPS) | 6.69 |
| Bruttomarginal | 65.63% |
| Nettovinstmarginal | 11.41% |
| Skuld/egenkapitalförhållande | 32.4% |
Hur har ACT0 utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
1.3%
Aktuell utdelningsavkastning31%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/18 19:58 |
| Aktiekurs vid dagens slut | 2026/09/18 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
AlzChem Group AG bevakas av 9 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Gerhard Orgonas | Berenberg |
| Julia Winckelmann | BofA Global Research |
| Manuela Stuerzer | Deutsche Bank |